Beckman Coulter, of Fullerton, Calif., a developer of automated complex biomedical tests, and San Diego-based Biosite, a biomedical company commercializing proteomics discoveries, have entered into a definitive merger agreement under which Beckman Coulter will acquire all of Biosite's outstanding common stock in a cash tender offer of $85 per share, or about $1.55 billion on a fully diluted share basis. (BioWorld Today)

Beckman Coulter, of Fullerton, Calif., a developer of automated complex biomedical tests, and San Diego-based Biosite, a biomedical company commercializing proteomics discoveries, have entered into a definitive merger agreement under which Beckman Coulter will acquire all of Biosite's outstanding common stock in a cash tender offer of $85 per share, or about $1.55 billion on a fully diluted share basis. (BioWorld Today)